IRVINE, Calif., Jan. 30, 2019 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today will celebrate the official opening of its most recent Global Logistics Center, based in Amsterdam, The Netherlands. The ribbon-cutting ceremony will be attended by Cryoport clients, governmental dignitaries and business partners. The new Global Logistics Center is located at Parellaan 18, 2132 WS Hoofddorp, near the Schiphol Amsterdam Airport, which serves as The Netherland's main aviation hub for international air traffic.
Opening this new state-of-the-art Global Logistics Center in Amsterdam strategically adds to Cryoport's global network supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls. Cryoport's "Chain of Compliance™" processes will be employed at the new facility, which was built so that it can be rapidly scaled to support additional demand for services. Cryoport clients, including Gilead Sciences, Novartis, Bellicum Pharmaceuticals, Immatics, Janssen Pharmaceuticals, and others, will benefit from Cryoport's new Global Logistics Center.
Amsterdam is a world-leading hub for the life sciences industry as a result of the region's many cutting-edge researchers, startups and collaborations, favorable import and export environment, and significant transit infrastructure. In January 2019, the European Medicines Agency moved its headquarters to Amsterdam, joining other major institutes including The Netherlands Cancer Institute and the Sanquin Blood Supply Foundation. Amsterdam supports the life sciences industry in many ways including the Amsterdam Science Park, an incubator for the development of healthcare businesses and special support of areas around the Schiphol Amsterdam Airport and the Port of Amsterdam, which offers strategic logistics hub locations.
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "The demand for comprehensive global support of regenerative therapies is growing rapidly. We are happy to add Amsterdam to our global network with its excellent connectivity and reputation as one of Europe's leading life sciences hubs. Choosing this strategic locating for our newest Global Logistics Center allows us to more effectively support our global biopharmaceutical client base throughout the research, clinical and commercialization phases of their revolutionary regenerative therapies. We would also like to thank the Dutch regulatory officials who worked so effectively to accommodate and welcome us to Amsterdam."
About Cryoport, Inc.
Cryoport is a trusted global provider of temperature controlled logistics solutions for life sciences commodities during distribution, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2017 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.